The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Follow-up Of Women On A Randomised Clinical Trial Of Adjuvant Docetaxel And Doxorubicin For Node Positive Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$113,250.00
Summary
This project is testing the use of a drug docetaxel in the post-operative (adjuvant) treatment of women with breast cancer and involved lymph nodes (N+). Until recently the drug doxorubicin was the most active chemotherapy drug for breast cancer, but more recently a new group of chemotherapy drugs called taxanes were identified. One taxane called docetaxel may be even more effective than doxoubicin. Using available treatments that include doxorubicin based chemotherapy, approximately half the wo ....This project is testing the use of a drug docetaxel in the post-operative (adjuvant) treatment of women with breast cancer and involved lymph nodes (N+). Until recently the drug doxorubicin was the most active chemotherapy drug for breast cancer, but more recently a new group of chemotherapy drugs called taxanes were identified. One taxane called docetaxel may be even more effective than doxoubicin. Using available treatments that include doxorubicin based chemotherapy, approximately half the women with N+ breast cancer experience recurrence of their cancer. It is therefore important to test whether the inclusion of docetaxel in adjuvant therapy can reduce relapses. If docetaxel is to be included, it is also important to test whether it is best to combine it with doxorubicin at the same time (which for safety reasons requires the doses of each drug to be reduced), versus giving them sequentially at full dose. Currently, docetaxel is not approved nor funded for use in early breast cancer in Australia. There are several international trials testing the inclusion of taxanes in the adjuvant therapy of breast cancer. However this trial stands out, because all the women in the trial receive chemotherapy of at least 6 months. In some other trials, testing the possible benefit of adding a taxane, women in the control treatment group (who were randomised not to receive the taxane) received only 3 months of treatment, which makes it difficult to distinguish between longer treatment or addition of the taxane drug. This trial has completed international recruitment of 2890 women who will be carefully followed for 10 years. Australian and New Zealand centers recruited 20% of the women in the trial. After the women have been followed-up for 5 years the results of this trial will be analysed, presented and published and should provide reliable evidence about the potential benefit of adding docetaxel into adjuvant chemotherapy.Read moreRead less
Clinical Trial Of Adjuvant Docetaxel And Doxorubicin For Node Positive Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$185,135.00
Summary
This project is investigating the optimal use of docetaxel and doxorubicin in the treatment of women with breast cancer and involved lymph nodes (N+). Every year 3000 women in Australia, and over 400,000 worldwide are newly diagnosed with N+ breast cancer. Using available treatments more than 60% of these (5 per day in Australia, 4,500 each week worldwide) will die from breast cancer. The efficacy of adjuvant chemotherapy in early breast cancer is well established by the international overview c ....This project is investigating the optimal use of docetaxel and doxorubicin in the treatment of women with breast cancer and involved lymph nodes (N+). Every year 3000 women in Australia, and over 400,000 worldwide are newly diagnosed with N+ breast cancer. Using available treatments more than 60% of these (5 per day in Australia, 4,500 each week worldwide) will die from breast cancer. The efficacy of adjuvant chemotherapy in early breast cancer is well established by the international overview conducted by the Early Breast Cancer Trialist's Collaborative Group (EBCTCG). They have demonstrated the efficacy of adjuvant chemotherapy on reducing mortality and recurrence rates, but current regimens are far from optimal. Docetaxel (Taxotere), a new agent, has effectiveness and manageable side effects in the treatment of advanced breast cancer patients, and can plausibly improve outcomes for patients with early N+ breast cancer by optimal integration into current adjuvant chemotherapy regimens. This clinical trial is designed to compare whether it is advantageous to use docetaxel and-or doxorubicin in combination or sequentially with other currently available chemotherapy drugs.Read moreRead less
The neuronal synapse is very tightly regulated by proteins that control both the timing and the amount of neurotransmitter release and neuronal stimulation. Defects in this synaptic signal are linked to diseases including epilepsy, autism and dementia. In this study we will determine the molecular details of how proteins called SNAREs control neurotransmission in the human brain.
Designing Learning Spaces for Diversity, Inclusion and Participation. This project aims to provide evidence-based guidance on how to design and/or modify mainstream schools to make it easier for students with disabilities to participate. It seeks to inform architects, educators, and policy makers about disabled students' spatial requirements and to develop strategies and tools to support the process of co-designing schools with people with lived experience of disability. The outcomes will includ ....Designing Learning Spaces for Diversity, Inclusion and Participation. This project aims to provide evidence-based guidance on how to design and/or modify mainstream schools to make it easier for students with disabilities to participate. It seeks to inform architects, educators, and policy makers about disabled students' spatial requirements and to develop strategies and tools to support the process of co-designing schools with people with lived experience of disability. The outcomes will include an inclusive learning spaces design framework. This is expected to benefit all students' access and meaningful involvement in learning through the development of more inclusive learning spaces. The research is significant because it integrates previously dissociated knowledge from architecture, education and health.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE230100049
Funder
Australian Research Council
Funding Amount
$459,030.00
Summary
Towards automated Australian Sign Language translation. This project aims to address the computational modelling of Auslan. The project expects to generate knowledge by creating the largest Auslan dataset, enabling further advancements in this research area. The dataset will also play an essential role in other research fields, e.g., sign linguistics. Expected outcomes include the invention of the first Auslan recogniser and generator capable of distinguishing and synthesising 1000+ signs, repre ....Towards automated Australian Sign Language translation. This project aims to address the computational modelling of Auslan. The project expects to generate knowledge by creating the largest Auslan dataset, enabling further advancements in this research area. The dataset will also play an essential role in other research fields, e.g., sign linguistics. Expected outcomes include the invention of the first Auslan recogniser and generator capable of distinguishing and synthesising 1000+ signs, representing a substantial advancement towards fully automated Auslan translation. This should provide significant benefits for the Australian Deaf community, such as high-quality digital systems for education and communication, resulting in increased quality of life and inclusion in the Australian society.Read moreRead less